FindTrial
Sign In

To see wheather using dopamine,a drug used to increase Blood pressure in low dose which act as Vascular endothelial growth factor(VEGF) inhibitor, prevents development of sudden lung injury in presence of infection.

A Randomized control trial to determine effect of dopamine as vegf (Vascular endothelial growth factor) antagonist on development of acute lung injury in sepsis.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052798
Enrollment
100
Registered
2023-05-17
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R652- Severe sepsis

Interventions

Intervention1: Dopamine intravenous infusion (@3-4mcg/kg/min) will be started in Study group patients.: In study group (group-2) besides standard treatment as per ICU protocols along with dopamine inf

Sponsors

Shivam Agarwal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients (18-65yr) of either sex admitted in CCU with the diagnosis of sepsis based on sepsis-3 definition()Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Organ dysfunction can be identified as an acute change in total SOFA score >=2 points consequent to the infection. The baseline SOFA score can be assumed to be zero in patients not known to have pre-existing organ dysfunction), raised procalcitonin( >0.5), and identified source of infection.

Exclusion criteria

Exclusion criteria: 1. Sepsis Induced acute lung injury before admission of intensive care unit. 2. Patients with head injury 3. Patients with preexisting lung injury. 4. Patients with cardiovascular disease. 5. Critical care unit mortality or loss to follow up within 7 days of admission.

Design outcomes

Primary

MeasureTime frame
To determine the effect of dopamine as VEGF (vascular endothelial growth factor) inhibitor in preventing further progression of sepsis to Acute lung injury. Timepoint: VEGF levels will be measured at Daignosis of sepsis (Day 1) and at Day 7.—

Secondary

MeasureTime frame
1. To establish the relationship of VEGF level in severity of lung injury . 2. To correlate the survival benefit of Dopamine in patients with sepsis. 3. Length of CCU stay. 4. Any associated side effect of dopamine. Timepoint: till follow up of patient(discharge/death)—

Countries

India

Contacts

Public ContactShivam Agarwal

King George Medical University Lucknow

vinod123.doctor@gmail.com9415795564

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026